Plasma acylcarnitines and incident kidney outcomes in apparently healthy adults

Clicks: 4
ID: 333201
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #204 of 209 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 209 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Conventional diagnostic markers, such as eGFR or albuminuria, often detect established late stages of kidney disease missing early adaptive changes. Acylcarnitines (ACs), intermediates of mitochondrial fatty acid oxidation, have been suggested as markers of metabolic dysfunction and impaired energy metabolism, which are important processes in early kidney injury. However, their role as prognostic biomarkers for early kidney disease remains unclear. Aim To analyse ACs as an early prognostic biomarker for progression to kidney disease in an apparently healthy European population-based sample. Methods Data from 1 960 apparently healthy adults in a population-based cohort in Lausanne, Switzerland. Incident chronic kidney disease (CKD) was defined as progression to eGFR<60 mL/min/1.73 m² and eGFR trajectory as progression from eGFR >90 mL/min/1.73 m² to eGFR 60-90 mL/min/1.73 m² during the follow-up period. Results Over a median follow-up of 8.5 years, 53 participants (2.7%) developed CKD, and 365 participants (18.4%) developed eGFR trajectory. In multivariate analyses, long-chain ACs (Arachidonyl-) remained positively associated with incident CKD and their baseline standardized log-transformed concentrations AC levels were higher. Baseline levels of short-chain ACs (Butyryl- and Hydroxybutyryl-), long-chain ACs (Tetradecanedienoyl-, Hexadecenoyl-, Stearoyl- and Oleoyl-) were significantly higher in the participants who later developed eGFR trajectory. Conclusion ACs were independently associated with both incident CKD and eGFR trajectory in healthy adults free from diabetes, obesity or cardiovascular disease. However, the findings of the current study cannot establish the clinical utility of ACs profiling as a prognostic marker for prognostic CKD and require confirmation in studies with sufficient events.
Reference Key
openalex_W7223188667 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ko Ko Maung, Nora Schwotzer, Rébecca Borreggine, Héctor Gallart‐Ayala, Julijana Ivanišević, Marc Froissart, Pedro Manuel Marques-Vidal
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag355
URL
https://doi.org/10.1093/ckj/sfag355
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.